Clinical Trial Update: Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases [NA]

View source ↗

Summary

Clinical trial update on a Gallium-68 labeled PSMA PET/CT tracer being studied to differentiate radiation necrosis from tumor progression in brain metastases; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Ga-68 PSMA PET/CT tracer (PSMA-11) (Gallium-68 labeled PSMA ligand)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Melanoma | NA | Status: RECRUITING